About
Contura International is a private limited company based in London, United Kingdom, with a manufacturing facility in Copenhagen, Denmark. Founded in January 2021, the company operates in the pharmaceutical sector, specializing in the development and manufacturing of basic pharmaceutical products. The company is known for its patented injectable polyacrylamide hydrogel, 2.5% iPAAG, which is designed for medical applications such as soft tissue augmentation, orthopaedics, and animal health. Their lead product, Arthrosamid®, targets osteoarthritis in the knee and was set to launch in the European market in late 2021. Contura's hydrogel technology offers long-lasting symptom relief and promotes integration with biological tissues, making it suitable for minimally invasive treatments. Contura International prioritizes quality, safety, and efficacy, adhering to strict manufacturing standards compliant with FDA and EU regulations. Their automated manufacturing plant ensures high-quality production, supported by rigorous testing and monitoring. The company holds multiple certifications, including GMP authorizations and ISO 13485, reflecting its commitment to quality management in medical device manufacturing.
Technologies
Keywords
Company Information
-
Employees 98
-
Founded 2000
-
Annual Revenue $3900000
Location
14 Took's Court, London, England, United Kingdom, EC4A 1LB
